Back

Angiographic derived physiological assessment after intervention for predicting 2-year vessel-oriented composite endpoints in Multivessel TALENT trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Intravascular imaging / physiology: guiding PCI to improve outcomes Percutaneous Coronary Intervention (PCI) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Shigetaka KAGEYAMA

Shizuoka City Hospital, Shizuoka (Japan)

5 More presentations in this session

Presentation thumbnail
Changes in high-sensitivity troponin according to optical characteristics of neointima and treatment modality of in-stent restenosis
Doctor N. Nano (Munich, DE)
Abstract Slides
Presentation thumbnail
Clinical relevance of impaired physiological assessment after percutaneous coronary intervention: a meta-analysis
Professor R. van Geuns (Nijmegen, NL)
Abstract Slides
Presentation thumbnail
Side effects and major adverse cardiac events caused by fractional flow reserve measurement: a systematic review and meta-analysis of 12,215 patients
Mr J. Altstidl (Erlangen, DE)
Abstract Slides
Presentation thumbnail
Correlation of FFR measured after DES implantation with clinical parameters and long-term clinical outcome
Doctor B. Csanadi (Budapest, HU)
Abstract Slides
Presentation thumbnail
Pathological analysis of struts coverage after second- and third-generation drug-eluting stents implantation for duration of dual anti-platelets therapy; an autopsy study
Mr K. Aihara (Kanagawa, JP)
Abstract Slides

Access the full session

Session thumbnail
Intravascular imaging / physiology: guiding PCI to improve outcomes

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Percutaneous intervention is better than surgery in real life for most patients: pro
thumbnail
Congress Presentation
Association of PCI with outcomes in stable coronary artery disease
thumbnail
Congress Presentation
Prognostic impact of intravascular imaging in percutaneous coronary intervention according to atherothrombotic risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources